Clinical Evidence: What UK Weight Loss Trials Actually Show
Wegovy or Mounjaro: Understanding the Clinical Evidence from UK Trials
When evaluating Wegovy or Mounjaro for weight management, UK patients increasingly rely on robust clinical evidence rather than anecdotal reports. The STEP trial programme for Wegovy (semaglutide) demonstrated that patients taking the medication alongside a reduced-calorie diet and increased physical activity achieved approximately 15% average weight loss at 68 weeks, as published by Wilding et al. in the New England Journal of Medicine, 2021. Meanwhile, Mounjaro's SURMOUNT trials showed different results using tirzepatide's dual GIP+GLP-1 mechanism, though direct comparisons remain challenging due to different trial designs and patient populations.
Understanding these evidence-based outcomes helps UK patients make informed decisions about Wegovy or Mounjaro treatment options. The STEP 5 extension study particularly demonstrated that Wegovy's weight loss benefits remained sustained at approximately 15.2% after two years of continuous treatment. However, both medications require long-term commitment, as the STEP 1 extension revealed that patients regained approximately two-thirds of weight lost within one year of stopping treatment, emphasising that weight management represents a long-term health commitment rather than a short-term intervention.
Wegovy or Mounjaro Pricing: Complete UK Cost Breakdown
EverydayMeds provides transparent pricing for both Wegovy or Mounjaro options, ensuring UK patients understand the complete cost structure before beginning treatment. Wegovy pricing starts at £79.99 for the initial 0.25mg dose (weeks 1-4) when using discount code FIRST40 for new customers, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to the maintenance dose of 2.4mg at £209.99. Our Getting Started bundles provide convenient dose progression, such as the Intro Duo (0.25mg & 0.5mg) for £169.99, whilst our Ultimate Stability Trio offers three months of maintenance supply at £649.99.
Returning customers benefit from the DOSE25 discount code applied at checkout, making ongoing Wegovy or Mounjaro treatment more accessible for long-term weight management. Our bundle system provides convenience through fewer orders and Reliable Supply continuity, particularly important given the need for consistent weekly dosing. All prices include prescriber review, clinical assessment processing, and next-day cold-chain delivery once treatment approval is confirmed by our GPhC-registered clinical team (#9012878).
How Wegovy or Mounjaro Work: Mechanism Differences Explained
The fundamental difference between Wegovy or Mounjaro lies in their hormonal mechanisms, which may influence treatment selection for individual patients. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural incretin hormone responsible for appetite regulation and glucose control. This mechanism reduces appetite, promotes feelings of fullness after smaller meals, and may reduce food cravings by acting on brain appetite centres. Mounjaro utilises tirzepatide, which activates both GIP and GLP-1 receptors simultaneously, creating a dual incretin effect that some studies suggest may provide enhanced weight loss potential.
Both treatments require weekly subcutaneous injection using pre-filled pen devices and must be used alongside a reduced-calorie diet and increased physical activity. The choice between Wegovy or Mounjaro often depends on individual response patterns, medical history, and prescriber recommendations based on clinical assessment outcomes.
Wegovy or Mounjaro Ordering Process: Clinical Assessment to Delivery
Accessing Wegovy or Mounjaro through EverydayMeds follows a structured clinical pathway designed to ensure treatment safety and appropriateness. The process begins with our comprehensive 3-minute online clinical assessment, covering medical history, current medications, weight management goals, and previous treatment experiences. Following submission, our qualified prescribers review applications within standard 3 working days, or 24 hours using our express service option. Once approved, both Wegovy or Mounjaro are dispatched via next-day delivery using specialised cold-chain packaging to maintain medication stability throughout transport.
Storage and Practical Considerations for Wegovy or Mounjaro
Practical storage requirements differ between Wegovy or Mounjaro, potentially influencing treatment choice for frequent travellers or those with limited refrigeration access. Wegovy pens must be stored at 2-8°C before first use but can remain at room temperature below 30°C for up to 6 weeks once removed from refrigeration, providing greater flexibility for travel or workplace storage. Both medications utilise user-friendly pen injection systems, with Wegovy's FlexTouch device offering dose confirmation windows and safety features. Dose escalation follows mandatory protocols, starting at 0.25mg weekly and gradually increasing to maintenance levels over 16 weeks to minimise potential side effects.
Real-World UK Outcomes: Wegovy or Mounjaro Patient Experiences
UK clinical practice data suggests that patients respond differently to Wegovy or Mounjaro, with individual factors influencing treatment outcomes beyond clinical trial averages. The SELECT cardiovascular outcomes trial demonstrated that Wegovy users experienced a 20% reduction in major cardiovascular events, highlighting benefits beyond weight management for appropriate patient populations. Patient reporting indicates that appetite reduction typically becomes noticeable within 2-4 weeks of starting either treatment, though optimal weight loss results generally require 12-16 weeks of consistent dosing alongside lifestyle modifications.
Long-term success with Wegovy or Mounjaro depends significantly on sustained behaviour changes, professional support, and realistic expectation setting. Our clinical team at EverydayMeds provides ongoing guidance throughout treatment, helping patients navigate dose adjustments, manage potential side effects, and maintain motivation during plateau periods that commonly occur during extended weight management programmes.
Medical Suitability: Who Can Access Wegovy or Mounjaro Treatment
Eligibility for Wegovy or Mounjaro follows MHRA licensing criteria, requiring BMI ≥30 kg/m², or BMI ≥27 kg/m² with weight-related comorbidities such as type 2 diabetes, hypertension, or dyslipidaemia. Both treatments are prescription-only medicines requiring thorough medical assessment before initiation, particularly for patients with personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease. NICE guidance (TA875) recommends Wegovy with specialist weight management support, whilst Mounjaro evaluation continues through ongoing real-world evidence collection.
Contraindications and cautions apply equally to Wegovy or Mounjaro treatment, including pregnancy, breastfeeding, and concurrent use of certain medications. Our prescribers conduct comprehensive medication reviews during clinical assessment to identify potential interactions or contraindications that might influence treatment selection or require additional monitoring throughout therapy.
Starting Your Wegovy or Mounjaro Journey with EverydayMeds
Beginning treatment with either Wegovy or Mounjaro through EverydayMeds ensures access to genuine medication, expert clinical oversight, and ongoing support throughout your weight management journey. New customers can apply discount code FIRST40 at checkout, whilst returning patients use DOSE25 to access our competitive pricing structure. Our GPhC-registered pharmacy (#9012878) maintains strict quality standards for medication storage, handling, and distribution, ensuring you receive authentic treatment with full cold-chain integrity. Complete your clinical assessment today to discover whether Wegovy or Mounjaro aligns with your health goals, medical history, and lifestyle requirements under expert prescriber guidance.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
